Zelicapavir is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase II drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zelicapavir LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Enanta Pharmaceuticals overview
Enanta Pharmaceuticals (Enanta) is a clinical-stage biotechnology company that develops small molecule drugs for viral infections. The company’s pipeline includes glecaprevir, EDP-514, EDP-938, EDP-323, EDP-235, EDP-305, EDP – 297.h Its pipeline candidates treat hepatitis C virus (HCV), Hepatitis B virus (HBV), respiratory syncytial virus (RSV), COVID-19 and non-alcoholic steatohepatitis (NASH). Its brands include Mavyret and Vieira pak. The company works in partnership with the National Institute of Allergy and Infectious Diseases, AbbVie Inc, Novartis, Shionogi Inc to discover two protease inhibitor compounds. Enanta is headquartered in Watertown, Massachusetts, the US.
For a complete picture of Zelicapavir’s drug-specific PTSR and LoA scores, buy the report here.